Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gurnet Point Capital
Cambridge, Massachusetts, United Statesgurnetpointcapital.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Gurnet Point Capital is not a drug developer but an active healthcare/life science investment firm; its portfolio includes several companies in late-stage clinical and commercial phases, such as Paratek Pharmaceuticals (antibiotics), Radius Health (osteoporosis), and Naveris (cancer diagnostics)[1][3][9].
- Modalities
- Small moleculePeptidesDiagnostic deviceDrug delivery therapyBiologicRecombinant protein
- Industry
- Investors
02
Partnerships
Paratek PharmaceuticalsCorium InnovationsRadius HealthNaverisBiohaven PharmaceuticalsCorvidia TherapeuticsPronutria Biosciences[1][2][3]
Beyond the preview
Go deeper on Gurnet Point Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gurnet Point Capital.